Results 101 to 110 of about 28,679 (139)
Correction to Cholesterol-Amino-Phosphate (CAP) Derived Lipid Nanoparticles for Delivery of Self-Amplifying RNA and Restoration of Spermatogenesis in Infertile Mice. [PDF]
Adv Sci (Weinh)europepmc +1 more source
Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines
Journal of Controlled Release, 2021 Self-amplifying RNA (saRNA) is a next-generation vaccine platform, but like all nucleic acids, requires a delivery vehicle to promote cellular uptake and protect the saRNA from degradation. To date, delivery platforms for saRNA have included lipid nanoparticles (LNP), polyplexes and cationic nanoemulsions; of these LNP are the most clinically advanced ...
Paul Mckay +2 more
exaly +4 more sources
Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA [PDF]
Molecular Therapy, 2021 Self-amplifying RNA (saRNA) is a cutting-edge platform for both nucleic acid vaccines and therapeutics. saRNA is self-adjuvanting, as it activates types I and III interferon (IFN), which enhances the immunogenicity of RNA vaccines but can also lead to inhibition of translation.
Paul Mckay +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Polyplex nanomicelle delivery of self-amplifying RNA vaccine
Journal of Controlled Release, 2021Self-amplifying RNA (SaRNA) is a burgeoning platform that exploits the replication machinery of alphaviruses such as Venezuelan equine encephalitis (VEE) virus or Sindbis virus (SIN). SaRNA has been used for development of human vaccines, but has not been evaluated for porcine vaccine development.
Yi-Hao, Chang +7 more
openaire +2 more sources
Protein therapy with self-amplifying RNA
ScienceSelf-amplifying RNA improves heart function after myocardial infarction in mice and ...
Lien, Ervijn, Niek N, Sanders
openaire +2 more sources
Self-amplifying RNA COVID-19 vaccine
CellIn November 2023, Japan's Ministry of Health, Labour and Welfare granted regulatory approval of ARCT-154, a self-amplifying RNA COVID-19 vaccine developed by Arcturus Therapeutics. Clinical trials showed comparable safety and efficacy using a lower dose compared to the mRNA vaccine BNT162b2. To view this Bench-to-Bedside, open or download the PDF.
Christopher J, Wayne, Anna K, Blakney
openaire +2 more sources
The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA
Journal of Controlled ReleaseLipid nanoparticle (LNP) formulation plays a vital role in RNA vaccine delivery. However, further optimisation of self-amplifying RNA (saRNA) vaccine formulation could help enhance seroconversion rates in humans and improve storage stability. Altering either the ionisable or helper lipid can alter the characteristics and performance of formulated saRNA
Paul Mckay +2 more
exaly +4 more sources
Self-amplifying RNA virus vectors for drug delivery
Expert Opinion on Drug DeliveryViral vectors have proven useful for delivering genetic information, such as drugs and vaccines, for therapeutic and prophylactic interventions. Self-amplifying RNA viruses possess the special feature of high-level RNA amplification in the host cell cytoplasm providing high antigen production against infectious pathogens and various types of cancers ...
openaire +2 more sources
A reversible small-molecule-switchable self-amplifying RNA expression platform
International Journal of Biological MacromoleculesRNA-based therapeutics offer versatile strategies for disease prevention and treatment, yet precise control over gene expression remains a major challenge. Self-amplifying RNA (saRNA), derived from the alphavirus genome, could be engineered to contain multiple subgenomic promoters, providing a unique RNA-only architecture for modular and independent ...
Guibin, Lin +3 more
openaire +2 more sources